Annual CFF
$410.91 M
+$49.83 M+13.80%
December 31, 2024
Summary
- As of March 10, 2025, SYRE annual cash flow from financing activities is $410.91 million, with the most recent change of +$49.83 million (+13.80%) on December 31, 2024.
- During the last 3 years, SYRE annual CFF has risen by +$409.51 million (+29397.92%).
- SYRE annual CFF is now at all-time high.
Performance
SYRE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$225.60 M
+$212.82 M+1665.27%
December 31, 2024
Summary
- As of March 10, 2025, SYRE quarterly cash flow from financing activities is $225.60 million, with the most recent change of +$212.82 million (+1665.27%) on December 31, 2024.
- Over the past year, SYRE quarterly CFF has stayed the same.
- SYRE quarterly CFF is now at all-time high.
Performance
SYRE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$410.91 M
+$61.99 M+17.77%
December 31, 2024
Summary
- As of March 10, 2025, SYRE TTM cash flow from financing activities is $410.91 million, with the most recent change of +$61.99 million (+17.77%) on December 31, 2024.
- Over the past year, SYRE TTM CFF has stayed the same.
- SYRE TTM CFF is now -22.94% below its all-time high of $533.23 million, reached on March 31, 2024.
Performance
SYRE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SYRE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.8% | 0.0% | 0.0% |
| 3 y3 years | +10000.0% | +10000.0% | +860.8% |
| 5 y5 years | +525.2% | +10000.0% | +860.8% |
SYRE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | at high | +1900.3% | -22.9% | >+9999.0% |
| 5 y | 5-year | at high | >+9999.0% | at high | +1900.3% | -22.9% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | at high | +1900.3% | -22.9% | >+9999.0% |
Spyre Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $410.91 M(+13.8%) | $225.60 M(+1665.3%) | $410.91 M(+17.8%) |
| Sep 2024 | - | $12.78 M(+3450.0%) | $348.91 M(+7.8%) |
| Jun 2024 | - | $360.00 K(-99.8%) | $323.60 M(-39.3%) |
| Mar 2024 | - | $172.16 M(+5.2%) | $533.23 M(+47.7%) |
| Dec 2023 | $361.08 M(+746.0%) | $163.61 M(-1405.6%) | $361.08 M(+82.9%) |
| Sep 2023 | - | -$12.53 M(-106.0%) | $197.46 M(-5.9%) |
| Jun 2023 | - | $209.99 M(>+9900.0%) | $209.86 M(+391.8%) |
| Mar 2023 | - | $10.00 K(-225.0%) | $42.68 M(-0.0%) |
| Dec 2022 | $42.68 M(+2963.7%) | - | - |
| Dec 2022 | - | -$8000.00(-93.8%) | $42.68 M(-0.2%) |
| Sep 2022 | - | -$130.00 K(-100.3%) | $42.77 M(-2.9%) |
| Jun 2022 | - | $42.80 M(>+9900.0%) | $44.04 M(+4122.3%) |
| Mar 2022 | - | $12.00 K(-85.0%) | $1.04 M(-25.1%) |
| Dec 2021 | $1.39 M(-99.1%) | $80.00 K(-93.0%) | $1.39 M(-94.6%) |
| Sep 2021 | - | $1.14 M(-695.3%) | $25.99 M(+3.5%) |
| Jun 2021 | - | -$192.00 K(-153.0%) | $25.11 M(-83.8%) |
| Mar 2021 | - | $362.00 K(-98.5%) | $154.59 M(+0.1%) |
| Dec 2020 | $154.51 M(+135.1%) | $24.68 M(+9465.5%) | $154.51 M(+18.4%) |
| Sep 2020 | - | $258.00 K(-99.8%) | $130.51 M(-0.0%) |
| Jun 2020 | - | $129.29 M(>+9900.0%) | $130.56 M(>+9900.0%) |
| Mar 2020 | - | $282.00 K(-58.3%) | $950.00 K(-98.6%) |
| Dec 2019 | $65.72 M | $676.00 K(+117.4%) | $65.72 M(-20.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | $311.00 K(-197.5%) | $82.31 M(-0.9%) |
| Jun 2019 | - | -$319.00 K(-100.5%) | $83.05 M(-31.6%) |
| Mar 2019 | - | $65.06 M(+276.9%) | $121.44 M(+112.8%) |
| Dec 2018 | $57.07 M(+367.3%) | $17.26 M(+1534.6%) | $57.07 M(+40.9%) |
| Sep 2018 | - | $1.06 M(-97.2%) | $40.49 M(+3.0%) |
| Jun 2018 | - | $38.06 M(+5432.4%) | $39.32 M(+207.0%) |
| Mar 2018 | - | $688.00 K(+0.6%) | $12.80 M(+4.8%) |
| Dec 2017 | $12.21 M(-75.3%) | $684.00 K(-679.7%) | $12.21 M(+5.9%) |
| Sep 2017 | - | -$118.00 K(-101.0%) | $11.53 M(-1.7%) |
| Jun 2017 | - | $11.55 M(>+9900.0%) | $11.72 M(-76.3%) |
| Mar 2017 | - | $96.00 K(>+9900.0%) | $49.56 M(+0.4%) |
| Dec 2016 | $49.37 M(+18.5%) | $0.00(-100.0%) | $49.37 M(+0.4%) |
| Sep 2016 | - | $76.00 K(-99.8%) | $49.17 M(+2.2%) |
| Jun 2016 | - | $49.39 M(<-9900.0%) | $48.12 M(-2389.3%) |
| Mar 2016 | - | -$98.00 K(-51.7%) | -$2.10 M(-105.0%) |
| Dec 2015 | $41.67 M(+647.5%) | -$203.00 K(-79.1%) | $41.67 M(-0.5%) |
| Sep 2015 | - | -$970.00 K(+16.7%) | $41.88 M(-13.5%) |
| Jun 2015 | - | -$831.00 K(-101.9%) | $48.42 M(-1.7%) |
| Mar 2015 | - | $43.68 M(>+9900.0%) | $49.25 M(+783.5%) |
| Dec 2014 | $5.58 M | $0.00(-100.0%) | $5.58 M(0.0%) |
| Sep 2014 | - | $5.58 M(>+9900.0%) | $5.58 M(>+9900.0%) |
| Jun 2014 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2014 | - | $0.00 | $0.00 |
FAQ
- What is Spyre Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Spyre Therapeutics?
- What is Spyre Therapeutics annual CFF year-on-year change?
- What is Spyre Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly CFF year-on-year change?
- What is Spyre Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Spyre Therapeutics?
- What is Spyre Therapeutics TTM CFF year-on-year change?
What is Spyre Therapeutics annual cash flow from financing activities?
The current annual CFF of SYRE is $410.91 M
What is the all time high annual CFF for Spyre Therapeutics?
Spyre Therapeutics all-time high annual cash flow from financing activities is $410.91 M
What is Spyre Therapeutics annual CFF year-on-year change?
Over the past year, SYRE annual cash flow from financing activities has changed by +$49.83 M (+13.80%)
What is Spyre Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SYRE is $225.60 M
What is the all time high quarterly CFF for Spyre Therapeutics?
Spyre Therapeutics all-time high quarterly cash flow from financing activities is $225.60 M
What is Spyre Therapeutics quarterly CFF year-on-year change?
Over the past year, SYRE quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Spyre Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SYRE is $410.91 M
What is the all time high TTM CFF for Spyre Therapeutics?
Spyre Therapeutics all-time high TTM cash flow from financing activities is $533.23 M
What is Spyre Therapeutics TTM CFF year-on-year change?
Over the past year, SYRE TTM cash flow from financing activities has changed by $0.00 (0.00%)